Biolargo Stock Price, News & Analysis

BioLargo, Inc. (OTCQB:BLGO) announced an investor webcast and conference call on November 16, 2022, at 2:00 PM Pacific/5:00 PM Eastern. The session will cover financial results for the three and nine months ending September 30, 2022, recent milestones, and a Q&A. Attendees can access the live broadcast via this link. BioLargo specializes in sustainable technologies and environmental engineering, holding numerous patents and partnerships aimed at addressing environmental challenges.

BioLargo, Inc. (OTCQB:BLGO) announced key results from its municipal wastewater treatment pilot at a conference in Halifax, Nova Scotia. The company showcased its patented Advanced Oxidation System (AOS), demonstrating a significant improvement in removing pharmaceutical micropollutants from wastewater. Over 18 months of testing at a facility near Montreal, the AOS increased removal efficiency to 84%-100%, compared to less effective current technologies. The company aims to position the AOS as a leader in the expanding market for micropollutant treatment as regulatory concerns grow worldwide.

BioLargo, Inc. (OTCQB: BLGO) announced the addition of two new board members, Linda Park and Christina Bray, enhancing its leadership team. Park, an executive with over 20 years of experience in corporate governance, previously worked with Edward Lifesciences and Western Digital. Bray, a finance specialist and CEO of Bluedot Energies, is recognized for her expertise in renewable energy technologies and capital projects. The company aims to leverage their experience to advance its cleantech vision. Retiring board members have transitioned to advisory positions.

BioLargo, Inc. (OTCQB:BLGO) reported a new quarterly revenue record of approximately $1.5 million for Q3 2022, up 13% from Q2 2022 and 111% year-over-year. The company’s growth was driven primarily by sales of its POOPH pet odor product. CEO Dennis P. Calvert emphasized ongoing expansion efforts and upcoming launches, including a PFAS removal project and consumer product rollouts. The full financial results are expected to be filed with the SEC by November 14, 2022, along with a planned investor webcast.

BioLargo, Inc. (OTCQB:BLGO) has entered a channel partnership agreement with Product Recovery Management (PRM), based in Butner, NC, to distribute BioLargo's water treatment systems and serve as a contract manufacturer. PRM will sell and distribute innovative technologies such as the Aqueous Electrostatic Concentrator (AEC) and Advanced Oxidation System (AOS), focusing on PFAS contamination solutions. This collaboration aims to leverage PRM's manufacturing capabilities and expertise in environmental remediation to meet growing demand for effective water treatment solutions.

BioLargo, Inc. (OTCQB:BLGO) reported strong growth in its quarterly report for Q2 2022, with consolidated revenue reaching $1.32 million, marking a 185% increase year-over-year. The company's subsidiaries, ONM Environmental and BioLargo Engineering, recorded significant revenue gains and returned to net operating income. BioLargo secured its first PFAS client, expanding its commercial reach, particularly with its white-label pet odor control product, POOPH. Upcoming projects with Garratt-Callahan and continuing engineering initiatives indicate a positive outlook.

BioLargo, Inc. (OTCQB:BLGO) will hold a public investor webcast and conference call on August 17, 2022, at 1:00 PM Pacific / 4:00 PM Eastern. The session aims to discuss the company's financial results for the six months ending June 30, 2022, review recent milestones, and engage in a Q&A. Interested participants can access the webcast via a provided link and join the teleconference using specified numbers. The event also serves to highlight BioLargo's innovative solutions in environmental technology.

BioLargo, Inc. (OTCQB:BLGO) has announced securing its first customer for a PFAS mitigation plan and establishing a partnership to market its PFAS treatment equipment. The customer contract marks the beginning of a multi-phase project aimed at addressing per- and polyfluoroalkyl substances (PFAS), which are harmful chemicals affecting health and the environment. The new channel partner will aid in distributing the company's engineering services and treatment technologies, including the proprietary Aqueous Electrostatic Concentrator (AEC).

BioLargo, Inc. (OTCQB:BLGO) reported approximately $1.3 million in revenue for Q2 2022, a 37% increase from Q1 and a 185% increase compared to Q2 2021. The company attributes this growth to expanding sales of the POOPH product, the anticipated launch of PFAS treatment technology, and larger engineering projects. The revenue figures are preliminary and may change pending accounting review. Full results will be available in the quarterly report due by August 15, 2022. An investor webcast will follow the report's release.